Sex-related differences in single nucleotide polymorphisms associated with dyslipidemia in a Korean population

Gyeonghee Lee1,2, Hye Kyung Jeon1,2 and Hae Young Yoo1*

Abstract
Background: The prevalence of dyslipidemia has increased steadily in Korea, and the incidence of dyslipidemia differs by sex. In this study, we identified single nucleotide polymorphisms (SNPs) related to dyslipidemia in Korean cohorts through genome-wide association study (GWAS) analysis.

Methods: Genotyping was conducted to determine the genotypes of 72,298 participants and investigate genotypes for 7,079,946 SNPs. Sex, age, and BMI were set as covariates for GWAS, and significant SNPs were identified in the discovery and replication stages using logistic regression.

Results: GWAS of the entire cohort revealed a total of five significant SNPs: rs117026536 (LPL), rs651821 (APOA5), rs9804646 (APOA5), rs9926440 (CETP), and rs429358 (APOE). GWAS of the male subjects revealed a total of four significant SNPs. While rs9804646 (APOA5) and rs429358 (APOE) were significant for all the subjects, rs662799 (APOA5) and rs56156922 (CETP) were significant only for the male subjects. GWAS of the female subjects revealed two significant SNPs, rs651821 (APOA5) and rs9804646 (APOA5), both of which were significant in all the subjects.

Conclusion: This is the first study to identify sex-related differences in genetic polymorphisms in Korean populations with dyslipidemia. Further studies considering environmental variables will be needed to elucidate these sex-related genetic differences in dyslipidemia.

Keywords: Genome-wide association analysis, Dyslipidemia, Sex-related difference, Single nucleotide polymorphism

Introduction
Dyslipidemia is defined as abnormal levels of blood lipids such as total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGs) and is a major cause of the deterioration of vascular function, which results in coronary heart disease (CHD) and stroke [1]. Plasma lipid levels are closely related to traditional CHD risk factors such as age, sex, family history, smoking, hypertension, diabetes mellitus, obesity, and a sedentary lifestyle [2–6]. Furthermore, genetic factors have a considerable influence on lipid metabolism [7]. Therefore, it is recommended that a person with certain risk factors or a family history of dyslipidemia must be screened at a young age [2, 6]. The prevalence of dyslipidemia has continued to increase in recent decades and shows a marked difference between men and women [8, 9]. The Korean Society of Lipid and Atherosclerosis (KSoLA) reported that the prevalence rate of dyslipidemia among Korean adults was 38.4% and was significantly higher in men than in women [8]. In men, dyslipidemia occurred most frequently in men aged 50–59 years and then gradually decreased thereafter; however, in women, the prevalence of dyslipidemia increased rapidly after menopause.
and exceeded the prevalence in men [10–12]. The rapid increase in the prevalence of dyslipidemia in women could be explained by hormonal changes caused by menopause. Estrogen decreases after menopause, leading to increased LDL-C and decreased HDL-C levels after menopause, especially with a decrease in HDL2-C, which is considered cardioprotective, thus increasing the risk of cardiovascular disease [12]. However, the cause of sex-related differences in the incidence of dyslipidemia has not been elucidated [13].

The levels of LDL-C, HDL-C, and TG interact with each other throughout metabolic processes [14, 15]. Patients are treated for dyslipidemia in the clinic, which takes into account multiple lipid levels rather than the individual lipid levels [10]. In GWAS, however, the interaction of each lipid level with regard to genetic variants was the main focus of SNP identification [16, 17]. Although studies examining the relationships between each lipid level and SNPs in the Korean cohort have been conducted, there have been relatively few that have included dyslipidemia [17]. Considering the metabolic relationship of each lipid level, studies on the association between dyslipidemia and related SNPs are necessary.

In this study, we investigated the genomes of individuals with dyslipidemia through a genome-wide association study (GWAS). This study was based on a method of screening genetic variations significantly affecting clinical or epidemiological variables among numerous single nucleotide polymorphisms (SNPs) present on the SNP chip (SNP microarray chip) [18]. GWAS enables the genetic analysis of individuals to enable the development of targeted preventive strategies for serious disease as well as the provision of individualized medical care [19]. With regard to dyslipidemia, GWAS in the Korean population has thus far been mainly performed using individual lipid levels (TG, TC, HDL-C, and LDL-C) or single gene-related associations; there are few studies on dyslipidemia and none analyzing the genetic association in dyslipidemia with sex [16]. Therefore, in this study, we identified SNPs related to dyslipidemia in a Korean population and identified genetic differences between men and women with dyslipidemia.

**Methods**

**Study subjects**

The study subjects were selected from the KoGES cohort. To analyze the correlation between dyslipidemia and genetic information with an emphasis on sex-related differences in Koreans, three datasets from the KoGES project were collected from the HEXA, CAVAS, and KARE cohort. In the discovery stage, an urban-based cohort (HEXA) was used for the GWAS analysis. Participants were recruited from Seoul, Busan, Incheon, Daegu, Gwangju, Ulsan, Anyang, Gyeonggi Province, Seongnam, Gwangwon, Cheonan, Jeonnam, Hwasun, South Jeolla Province, and Changwon, South Gyeongsang Province, from 2004 to 2013. The analysis included 15,054 dyslipidemia patients and 37,404 controls belonging to the HEXA cohort, with a total of 52,458 participants. Two independent Korean cohorts were used in the replication stage: a rural-based cohort (CAVAS) and a community-based cohort (KARE). The CAVAS cohort was recruited from 2001 to 2002 and comprised 40–69-year-old men and women living in rural areas of Korea: Yangpyeong, Goryeong in Gyeongsangbuk-do, Namwon in Jeonnam, Wonju and Pyeongchang in Gangwon-do, and Ganghwa in Incheon. We used 2743 dyslipidemia patients and 2918 controls in the CAVAS cohort for analysis. The KARE cohort was recruited from 2001 to 2002 and comprised men and women aged 40–69 years living in Ansan and Anseong in Gyeonggi-do. The analysis included 2309 dyslipidemia patients and 3184 controls from the KARE cohort.

**Biochemical measurements**

The general and clinical characteristics of the subjects were obtained from data collected through self-report questionnaires and physical examination in the Korean Genome and Epidemiology Study (KoGES). We analyzed sex, age, BMI, TC, LDL-C, HDL-C, and TGs in this study. According to The Korean Society of Lipid and Arteriosclerosis Korean Guidelines for the management of dyslipidemia, dyslipidemia is defined as one or more cases where TC is > 240 mg/dL, LDL-C is > 160 mg/dL, TGs are > 200 mg/dL, and HDL-C is < 40 mg/dL [10]. Based on this diagnosis criterion, subjects were assigned to the patient group if the results of their fasting serum lipid levels satisfied at least one of the four criteria and to the control group when none of the criteria were met.

**Genotyping and quality control**

Genomic DNA samples were genotyped using the Korea Biobank Array (K-Chip), including genetic information from the HEXA, CAVAS, and KARE cohorts, designed by the Korea Centers for Disease Control and Prevention (KNIH, 4845–301, 3000–3031, [http://nh.go.kr/NIH_NEW/main.jsp](http://nh.go.kr/NIH_NEW/main.jsp)) and manufactured by Affymetrix. In this study, genotyping was conducted to determine the genotypes of 72,298 people and investigate the genotypes for 7,079,946 SNPs. SNP quality control (QC) operations were performed to purify the genomic data, and 5,344,653 SNPs were used after QC by applying minor allele frequency (MAF) < 0.05, SNP call rate < 0.95, and Hardy-Weinberg equal p value < 10−6 for practical analysis. A sorting operation was performed to distinguish between the HEXA, CAVAS, and KARE cohorts included
Table 1 Characteristics of all the study subjects

| Variables | Categories | HEXA (Discovery) | CAVAS (Replication) | KARE (Replication) |
|-----------|------------|------------------|---------------------|--------------------|
|           | Dyslipidemia (n = 15,054) | Nondyslipidemia (n = 37,395) | Dyslipidemia (n = 2743) | Nondyslipidemia (n = 2912) | Dyslipidemia (n = 2309) | Nondyslipidemia (n = 3184) |
| Sex       | Male       | 5848 (38.9) | 12,402 (33.2) | <0.001*** | 1104 (40.2) | 1043 (35.8) | <0.001*** | 1303 (56.4) | 1313 (41.2) | <0.001*** |
|           | Female     | 9206 (61.1) | 24,993 (66.8) |           | 1639 (59.8) | 1869 (64.2) |           | 1006 (43.6) | 1871 (58.8) |           |
| Age (years) | 58.58 ± 7.77 | 58.53 ± 8.30 | 0.087 | 60.89 ± 8.37 | 60.40 ± 9.02 | <0.05* | 52.1 ± 8.33 | 51.07 ± 8.60 | <0.001*** |
| BMI (kg/m²) | 24.54 ± 2.87 | 23.62 ± 2.92 | <0.001*** | 24.91 ± 3.04 | 23.91 ± 3.16 | <0.001*** | 25.37 ± 2.80 | 24.05 ± 2.98 | <0.001*** |
| TC (mg/dL)  | 224.51 ± 45.30 | 189.19 ± 27.96 | <0.001*** | 202.25 ± 41.41 | 189.77 ± 25.84 | <0.001*** | 213.78 ± 41.49 | 189.31 ± 26.39 | <0.001*** |
| HDL-C (mg/dL) | 51.21 ± 16.82 | 60.72 ± 73.73 | <0.001*** | 39.40 ± 9.99 | 51.70 ± 10.10 | <0.001*** | 43.37 ± 10.50 | 53.59 ± 10.24 | <0.001*** |
| TG (mg/dL)  | 184.01 ± 112.03 | 100.94 ± 37.24 | <0.001*** | 183.18 ± 96.22 | 107.19 ± 37.10 | <0.001*** | 216.86 ± 140.55 | 106.45 ± 38.68 | <0.001*** |
| LDL-C (mg/dL) | 138.84 ± 4.125 | 106.28 ± 26.08 | <0.001*** | 127.73 ± 37.74 | 116.63 ± 24.23 | <0.001*** | 130.89 ± 38.72 | 113.44 ± 24.91 | <0.001*** |

* M mean, SD standard deviation, P p value, BMI body mass index, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol, ***p < 0.001, ** p < 0.01, * p < 0.05
in the K-chip. In the GWAS, age, sex, and BMI were set as covariates, and the discovery stage was performed in the HEXA cohort using logistic regression analysis. The analysis of 25,448 out of 58,700 people in the HEXA cohort resulted in a total of 25 significant SNPs. These 25 SNPs were used to perform the replication stage on the CAVAS and KARE cohorts.

Statistical analysis
Statistical analyses were performed using PLINK (v.1.07, http://pngu.mgh.harvard.edu/purcell/plink/) to derive data refinement and SNPs from the genomic data. FUMA GWAS (https://www.nature.com/articles/s41467-017-01261-5) was used to interpret the data and represent SNPs found in all the study subjects, while rs9804646 was most associated with dyslipidemia (P = 1.25 × 10^{-52}); this association was maintained during the replication stage (CAVAS P = 1.02 × 10^{-6}, KARE P = 2.52 × 10^{-6}). Additionally, rs117026536 in the LPL gene, rs651821 in the CETP gene, and rs429358 in the APOE gene were associated with dyslipidemia. The GWAS analysis of the male subjects revealed 13 significant SNPs in the discovery stage (P < 5 × 10^{-8}) (Fig. 1B). It was confirmed through QQ plots that these SNPs were associated with dyslipidemia in males (Fig. 2B). In addition, a total of four significant SNPs were discovered in the replication stage that satisfied the Bonferroni-corrected cutoff (P < 2 × 10^{-3}). Table 2 shows the GWAS results for dyslipidemia for all the study subjects. The APOA5 gene rs9804646 was most associated with dyslipidemia (P = 1.25 × 10^{-52}); this association was maintained during the replication stage (CAVAS P = 1.02 × 10^{-6}, KARE P = 2.52 × 10^{-6}). Additionally, rs117026536 in the LPL gene, rs651821 in the CETP gene, and rs429358 in the APOE gene were associated with dyslipidemia. The GWAS analysis of the male subjects revealed 13 significant SNPs in the discovery stage (P < 5 × 10^{-8}) (Fig. 1B). It was confirmed through QQ plots that these SNPs were associated with dyslipidemia in males (Fig. 2B). In addition, a total of four significant SNPs were discovered in the replication stage that satisfied the Bonferroni-corrected cutoff (P < 2 × 10^{-3}). Table 3 shows the GWAS results for dyslipidemia in the male subjects. The APOA5 gene rs6627999 was most associated with dyslipidemia (P = 1.40 × 10^{-67}); this association was maintained during the replication stage (CAVAS P = 3.69 × 10^{-8}, KARE P = 1.47 × 10^{-11}). Additionally, rs9804646 in the APOA5 gene, as well as rs56156922 and rs429358 in the APOE gene, were associated with dyslipidemia. Among these SNPs, rs9804646 and rs429358 correspond to the key SNPs found in all the study subjects, while rs56156922 and rs662799 were found only in male subjects. The GWAS analysis of the female subjects revealed 12 significant SNPs in the discovery stage (P < 5 × 10^{-8}) (Fig. 1C). It was confirmed through QQ plots that these SNPs were associated with dyslipidemia in females (Fig. 2C). In addition, a total of two crucial SNPs were discovered in the

Results

Characteristics of the study subjects
Clinical features related to sex, demographics, and dyslipidemia in the Health EXAminnee (HEXA), the cardiovascular disease association study (CAVAS), and the community-based KARE cohorts are described in Table 1. The average age of the subjects was 58.54 years in the community-based KARE cohorts are described in Additional File 1: Table 1. The average age of the female study subjects was 57.80 years in the HEXA cohort at the discovery stage and 59.72 years in the CAVAS and KARE cohorts at the replication stage, respectively. Among the female study subjects, 9206 patients from the HEXA cohort at the discovery stage and 1639 and 1006 from the CAVAS and KARE cohorts at the replication stage, respectively, were included in the dyslipidemia group.

Clinical features related to demographics and dyslipidemia for male subjects in the HEXA (n = 34,199), CAVAS (n = 3508), and KARE (n = 2877) cohorts are described in Additional File 2: Table 2. The average age of the female study subjects was 57.80 years in the HEXA cohort at the discovery stage and 59.72 years in the CAVAS and KARE cohorts at the replication stage, respectively. Among the female study subjects, 9206 patients from the HEXA cohort at the discovery stage and 1639 and 1006 from the CAVAS and KARE cohorts at the replication stage, respectively, were included in the dyslipidemia group.
CETP are affected and appear as SNPs associated with blood chromosome 16q13 within the gene, all of which CETP [26]. Indeed, rs56156922 and these SNPs are located at to alter blood lipid levels of HDL-C, LDL, and TG [25, C-629A (rs1800775) and I405 V (rs5882) are known levels.

show sex-related differences in relation to blood lipid gene CETP to TG, LDL-C, and HDL-C. In addition, SNPs that exist SNPs found only in the male study subjects. Thus, these results indicate that there is a sex-related association between SNPs and dyslipidemia.

Discussion
This study attempted to identify genes related to dyslipidemia according to sex in Korean cohorts. We identified five dyslipidemia-related SNPs in the entire study population. We also tried to identify dyslipidemia-related SNPs according to sex by analyzing male and female cohorts separately. In men, four dyslipidemia-related SNPs were discovered, of which two were also found in the entire cohort. Of note, the other two SNPs, rs56156922 (CETP) and rs662799 (APOA5), appeared to be dyslipidemia-related SNPs found only in men. In contrast, two dyslipidemia-related SNPs were discovered in women, which were also commonly found in the entire cohort. These results confirm that there are sex-related differences in dyslipidemia-related SNPs.

Although rs56156922 located in the CETP gene was found to be related to HDL-C levels [22], this is the first report of sex-related differences in this SNP. The CETP gene is well known for producing CETP, which is a plasma protein that promotes the transport of triglycerides (TGs), exchanging them with cholesterol esters of HDL [23, 24]. Therefore, the CETP gene is closely related to TG, LDL-C, and HDL-C. In addition, SNPs that exist at a similar position to rs56156922 in the CETP gene show sex-related differences in relation to blood lipid levels. Taq1B (rs708272) and the CETP polymorphisms C-629A (rs1800775) and I405 V (rs5882) are known to alter blood lipid levels of HDL-C, LDL, and TG [25, 26]. Indeed, rs56156922 and these SNPs are located at chromosome 16q13 within the CETP gene, all of which are affected and appear as SNPs associated with blood lipid levels. Previous studies have shown that the CETP gene affects lipid levels differentially depending on the sex of the individuals [27–30]. In a study of the association between CETP and HDL-C concentrations in Jewish cohorts, the mean plasma CETP levels were higher in women than in men, whereas plasma CETP levels were inversely proportional to HDL-C in men but not in women [30]. The action of CETP generally increases the levels of TGs and LDL-C and lowers the level of HDL-C in a sex-independent manner. However, estrogen has an effect on LDL-C metabolism through LDL receptors and increases HDL-C synthesis by delaying the catabolism of HDL-C [31, 32]. We speculate that estrogen may also play a role in our study. Through the action of estrogen, the activity of CETP is reduced, indicating that premenopausal women have higher HDL-C and lower LDL-C concentrations than men or postmenopausal women [33, 34]. It is presumed that this action of CETP may have also influenced our results. The SNPs of CETP, including rs56156922, may not appear as dyslipidemia-related SNPs in female subjects due to the action of estrogen. Nevertheless, it is difficult to determine whether estrogen has a direct effect on these CETP mutations.

Interestingly, rs662799 of APOA5 also appeared as a dyslipidemia-related SNP only in the male cohort, indicating that there are sex-related differences in the prevalence of dyslipidemia. The APOA5 protein produced through the APOA5 gene is the main regulator of plasma triglyceride levels [35]. In the metabolic process of APOA5, it activates the metabolism of triglycerides and affects the production of LDL-C and HDL-C by inhibiting the production and assembly of VLDL particles [36]. Specifically, rs662799 of APOA5 is known as the SNP, which has a significant association in the Asian population, although it has little effect in the European population [37]. rs662799 of APOA5 is located at 11q23.3 on chromosome 11. A previous study of blood lipid levels as a major risk factor for CHD showed that rs662799 has a substantial effect on blood lipid levels, with a significant association with CHD in males in particular [38]. Thus, this SNP of APOA5 could be an important factor in explaining the variations in the incidence of CHD by sex and age, especially the higher incidence of CHD in men than in women due to its sex-specific effects on blood lipid levels [39, 40].

Another SNP of APOA5, rs9804646, which is located at 11q23.3, was found to be a dyslipidemia-related SNP in replication stage that satisfied the Bonferroni-corrected cutoff ($P<3 \times 10^{-3}$). Table 4 shows the GWAS results for dyslipidemia in the female subjects. The APOA5 gene rs9804646 was the most associated with dyslipidemia ($P=7.31 \times 10^{-87}$); this association was maintained during the replication stage (CAVAS $p=8.64 \times 10^{-3}$, KARE $P=4.29 \times 10^{-18}$). Moreover, rs651821 of the APOA5 gene was also shown to be associated with dyslipidemia. Significant SNPs in the female study subjects were also found in all the study subjects, unlike the significant SNPs found only in the male study subjects. Thus, these results indicate that there is a sex-related association between SNPs and dyslipidemia.
Fig. 1 (See legend on previous page.)
both the male and female cohorts. Although rs9804646 was found to be linked to dyslipidemia in previous studies on East Asian populations [41] and multiethnic populations consisting of East Asians, African Americans, and Hispanics, regardless of country [42], no links have been found in the Korean population. In addition to rs9804646, the SNP rs651821 in the female cohort was also present in APOA5 and was confirmed to have a significant association with dyslipidemia in the Korean population. Kim et al. showed that rs651821 had a major impact on plasma TG levels in the KoGES’ association analysis with the HEXA and KARE populations [17]. In addition, Gombojav et al. showed that rs6512821 has significant associations with plasma TG levels in the KARE and Healthy Twin Study population of KoGES [43].

rs9926440 of CETP was found to be another significant SNP in this study, appearing in the entire cohort. In another study examining various health indicators related to metabolic syndrome, such as blood pressure, blood sugar, and blood lipid levels, rs9926440 was found to be associated with obesity and metabolic syndrome in a Korean cohort [44]. In our study focused on blood lipid levels, rs9926440 was found to be strongly associated with dyslipidemia. Thus, the findings from previous [44] and current studies suggest that rs9926440 is highly correlated with chronic diseases such as metabolic syndrome and dyslipidemia in these Korean cohorts.

The analysis of the entire cohort revealed SNPs located in the LPL and APOE genes. As the LPL gene is associated with high levels of TG and HDL-C, SNPs of this gene would be expected to be found in the entire cohort in this study. The LPL gene encodes lipoprotein lipase (LPL), which converts VLDL to LDL through catalysis and functions in triglyceride hydrolysis. Mutations that cause LPL deficiency are highly associated with hyperlipidemia and various lipoprotein metabolic disorders [45]. Previous studies have shown that rs117026536 in the LPL gene was associated with high levels of TG and HDL-C in a non-Hispanic, white American population; however, no studies have been conducted in East Asian populations [46]. This study provides evidence that rs117026536 of the LPL gene is related to the occurrence of dyslipidemia in the Korean population. In our study, rs429358 in the APOE gene appeared in the male but not in the female subjects. APOE is a protein that carries lipids, fat-soluble vitamins and cholesterol into the blood and is produced by the APOE gene. Because of its function, it is a protein that
Table 2  Significant SNPs associated with dyslipidemia in the entire study

| CHR | POS     | SNP       | Gene    | Location of SNP | Minor allele | MAF | SE   | OR    | p-value | MAF | SE   | OR    | p-value | MAF | SE   | OR    | p-value |
|-----|---------|-----------|---------|----------------|---------------|-----|------|-------|---------|-----|------|-------|---------|-----|------|-------|---------|
| 8   | 8:19818773_G/T | rs117026536 | LPL     | intronic       | T             | 0.1256 | 0.02137 | 0.823 | 7.74E-20 | 0.1251 | 0.6964 | 0.05954 | 1.24E-09 | 1.25E-01 | 0.8262 | 0.05967 | 0.8262 | 0.05967 |
| 11  | 11:16662579_C/T | rs651821 | APOA5   | UTR5           | C             | 0.2988 | 0.01469 | 1.469 | 2.70E-15 | 0.2975 | 1.441 | 0.04253 | 8.61E-18 | 3.01E-01 | 1.536 | 0.04327 | 3.61E-23 |
| 11  | 11:16665079_C/T | rs9804646 | APOA5   | intergenic     | T             | 0.1572 | 0.01952 | 0.7928 | 1.25E-32 | 0.159 | 0.7745 | 0.05229 | 1.02E-06 | 1.59E-01 | 0.7725 | 0.05486 | 2.52E-06 |
| 16  | 16:57002663_C/G | rs9926440 | CETP    | intronic       | C             | 0.3132 | 0.01461 | 1.101 | 3.70E-11 | 0.3159 | 1.159 | 0.0411 | 0.000341 | 0.3112 | 1.177 | 0.04193 | 0.000104 |
| 19  | 19:45411941_T/C | rs429358 | APOE    | exonic         | C             | 0.09561 | 0.02239 | 1.298 | 2.14E-31 | 0.09556 | 1.366 | 0.06577 | 2.09E-06 | 9.93E-02 | 1.48 | 0.06531 | 1.97E-09 |

CHR chromosome, POS position, SNP single nucleotide polymorphism, MAF minor allele frequency, SE standard error, OR odds ratio
Table 3  Significant SNPs associated with dyslipidemia in the male subjects

| Male | Discovery | Replication |
|------|-----------|-------------|
|      | HEXA      | CAVAS       | KARE        |
| CHR  | POS       | SNP         | Gene        | Location of SNP | Minor allele | MAF  | SE  | OR  | p-value | MAF  | SE  | OR  | p-value | MAF  | SE  | OR  | p-value |
| 11   | 11:116663707_G/A | rs662799   | APOA5       | upstream    | G           | 0.2988 | 0.0245 | 1.53 | 1.40E-67 | 0.2975 | 0.0692 | 1.464 | 3.69E-08 | 0.3012 | 0.0623 | 1.523 | 1.47E-11 |
| 11   | 11:116665079_C/T | rs9804646  | APOA5       | intergenic  | T           | 0.1572 | 0.03249 | 0.765 | 1.64E-16 | 0.159 | 0.08539 | 0.7331 | 0.000278 | 0.1589 | 0.07805 | 0.7829 | 0.001717 |
| 16   | 16:56987369_T/C | rs56156922  | CETP        | intergenic  | C           | 0.1713 | 0.03093 | 0.8015 | 8.36E-13 | 0.1689 | 0.08472 | 0.7201 | 0.000107 | 0.1685 | 0.07429 | 0.7894 | 0.001452 |
| 19   | 19:45411941_T/C | rs429358   | APOE        | exonic      | C           | 0.09561 | 0.03746 | 1.334 | 1.50E-14 | 0.09566 | 0.1082 | 1.416 | 0.001289 | 0.09931 | 0.09677 | 1.556 | 4.96E-06 |

CHR chromosome, POS position, SNP single nucleotide polymorphism, MAF minor allele frequency, SE standard error, OR odds ratio
Table 4  Significant SNPs associated with dyslipidemia in the female subjects

| CHR | POS   | SNP      | Gene  | Location of SNP | Minor allele | MAF | SE | OR  | p-value | MAF | SE | OR  | p-value | MAF | SE | OR  | p-value |
|-----|-------|----------|-------|-----------------|--------------|-----|----|-----|--------|-----|----|-----|---------|-----|----|-----|---------|
| 11  | 11:116662579_C/T | rs651821 | APOA5 | UTR5            | T            | 0.2988 | 0.02449 | 0.8092 | 5.48E-18 | 0.2975 | 0.0544 | 1.437 | 2.64E-11 | 0.3014 | 0.06172 | 1.575 | 1.88E-13 |
| 11  | 11:116665079_C/T | rs9804646 | APOA5 | intergenic      | C            | 0.1572 | 0.01844 | 1.439 | 7.31E-18 | 0.159 | 0.06662 | 0.8099 | 0.0008636 | 0.1589 | 0.07908 | 0.7569 | 0.0004288 |

CHR chromosome, POS position, SNP single nucleotide polymorphism, MAF minor allele frequency, SE standard error, OR odds ratio
is highly related to various lipoprotein metabolism and cardiovascular diseases [47]. Previous studies have shown that rs429358 is linked to HDL-C, LDL-C, TC, and TG levels [48]. Indeed, rs429358 was correlated with TG levels in Korean type 2 diabetes patients [49] and with TG levels and metabolic syndrome in Korean subjects [50]. In addition, rs429358 has been linked to Alzheimer’s disease [51], dementia, and Parkinson’s disease. Of particular relevance to our results, the APOE gene has been shown to be associated with androgen, a sex hormone [52, 53], which can explain the sex-related differences in blood lipid levels observed with rs429358, a major SNP determining the genotype of the APOE gene.

This study focused on the discovery of SNPs related to dyslipidemia according to sex without including environmental factors or other characteristics. Therefore, a follow-up study is needed to analyze the interactions between environmental factors and dyslipidemia and investigate other sex-related characteristics, such as women’s age and hormone levels. Previous studies have also shown that the effects of diet, smoking, drinking, and physical activity on blood lipid levels and related gene polymorphisms differ between men and women [48]. Pregnant and premenopausal women are less likely to develop dyslipidemia due to the protective effects of estrogen [12]. Menopause reduces HDL-C and increases TG, TC, and LDL-C levels [54]; even healthy, postmenopausal women show increased insulin resistance and body and abdominal fat [55], which are highly linked to blood lipid levels [56]. Therefore, further studies on dyslipidemia and sex-related differences in dyslipidemia are needed.

**Study strengths and limitations**

The main strength of this study is that it is the first study conducted on Korean cohorts related to gender differences in dyslipidemia. Furthermore, the cohorts used in this study were organized by the government, making it reliable that the characteristics and biochemical measurements of Koreans were accurately included. Additionally, since three cohorts used in this study also reflect regional features of urban, rural, and community areas in Korea, they can represent dyslipidemia across the entirety of Korea. Finally, it can be considered as a study including the latest trend that needs integrated lipid management rather than each lipid level.

Despite its strengths, this study has several limitations. In this study, a p value of 0.05 or less was used when identifying SNPs; however, a p value considering multiple corrections based on different Korean population groups may be more appropriate. In addition, we used blood lipid levels to diagnose the development of dyslipidemia. However, dyslipidemia requires the consideration of all risk factors, such as coronary artery disease, peripheral vascular disease, and diabetes.

**Conclusion**

As a result of the genome-wide association study using Korean cohorts, it was confirmed that there is a gender difference in the genetic polymorphisms of dyslipidemia. The findings of this study support that in the treatment of dyslipidemia, both genetic features and gender characteristics should be considered and suggest the direction of customized medical care, which is one of the purposes of the GWAS in clinical practice. On the other hand, since environmental variables should be considered in dyslipidemia, further research is needed including health-related lifestyle factors that make gender differences. In addition, menopause is one of the main causes of specific differences in dyslipidemia that only appear in women compared to men. Therefore, follow-up studies should be conducted considering women’s menopause along with studies including environmental variables.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12944-022-01736-5.

**Acknowledgments**

This study was conducted with bioresources from the National Biobank of Korea and the Korea Disease Control and Prevention Agency (IRB-No.: 20191023-01736-5).

**Authors’ contributions**

GHL and HYY contributed to the project conception and participated in the study design. GHL, HY, and HKJ conducted the research. GHL performed the statistical analysis. GHL and HYY drafted the manuscript. GHL, HY, and HKJ revised the manuscript. HYY had primary responsibility for the final content. All authors read and approved the final manuscript.

**Funding**

This study was supported by a National Research Foundation of Korea grant funded by Ministry of Science, ICT, & Future Planning (NRF-2019R1F1A1062965) and the Chung-Ang University Research Scholarship Grants in 2021.

**Availability of data and materials**

The data used in this study are available after obtaining permission from the National Biobank of Korea from the National Human Resources Bank of Korea, the Center for Disease Control and Prevention, Republic of Korea.

**Declarations**

**Ethics approval and consent to participate**

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki Declaration its later amendments or comparable ethical standards. This study was exempted from the institutional review board (IRB) of Chung-Ang University (IRB No.: 1041078–201,908-HRBR-236-01).
Consent for publication

All participants in this study signed a written prior consent form for data collection. Participants signed informed consent forms regarding publication of their data.

Competing interests

The authors have declared no competing interests.

Author details

1 Department of Nursing, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Republic of Korea. 2 Graduate School, Chung-Ang University, Seoul 06974, Republic of Korea.

Received: 2 September 2022   Accepted: 14 November 2022

Published: 23 November 2022

References

1. Fodor G. Primary prevention of CVD: treating dyslipidaemia. BJM Clin Evid. 2008;2008:0215.
2. Kopin L, Lowenstein C. Dyslipidemia. Ann Intern Med. 2017;167:ITC81–96.
3. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circ. 2002;106:3143–421.
4. Berg AO, Atkins D. U.S Preventive services task force: screening for lipid disorders in adults: recommendations and rationale. Am J Nurs. 2002;102(9):95–3.
5. Barton M. Screening for obesity in children and adolescents: US preventive services task force recommendation statement. Pediatr. 2010;125(2):361–7.
6. Daniels SR, Greer FR, Greer FR, Bhatia JJ, Daniels SR, Schneider MB, et al. Lipid screening and cardiovascular health in childhood. Pediatr. 2008;122:198–208.
7. Yamada Y, Matsuo H, Wanta S, Watanabe S, Kato K, Oguri M, et al. Prediction of genetic risk for dyslipidemia. Genomics. 2007;90:551–8.
8. Cho SMJ, Lee H, Lee HH, Baek J, Heo JE, Joo HJ, et al. Dyslipidemia fact sheets in Korea 2020: an analysis of nationwide population-based data. J Lipid Atheroscler. 2021;10(2):202–9.
9. Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689–700.
10. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 guidelines for the Management of Dyslipidemia in Korea. J Lipid Atheroscler. 2019;8:78–131.
11. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badmon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J. 2019;41:111–88.
12. Ha KH, Kwon H-S, Kim DJ. Epidemiologic characteristics of dyslipidemia in Korea. J Lipid Ather. 2015;4:93.
13. Phan BAP, Toth PP. Dyslipidemia in women: etiology and management. Int J Women's Health. 2014;6:185–194.
14. Klopf B, Wouter Jukema J, Rabellink TJ, Castro CM. A physician's guide for the management of hyperterglyceridemia: the etiology of hypertriacylglyceridemia determines treatment strategy. Panminerva Med. 2012;54:91–103.
15. Klopf B, Elke JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5:1218–40.
16. Kim T, Park AY, Baek Y, Cha S. Genome-wide association study reveals four loci for lipid ratios in the Korean population and the constitutional subgroup. PLoS One. 2017;12:e0168137.
17. Kim HK, Ahnwar MA, Choi S. Association of BUD13-ZNF259-APOA5-APOA1-SK5 cluster polymorphism in 11q23.3 and structure of APOA5 with increased plasma triglyceride levels in a Korean population. Sci Rep. 2019;9:8296.
18. Ueffelman E, Huang QQ, Munung NS, De Vries J, Okada Y, Martin AR, et al. Genome-wide association studies. Nat Rev Methods Primers. 2021;1:1–21.
19. Bush WS, Moore JH. Chapter 11: genome-wide association studies. PLoS Comput Biol. 2012;8:e1002822.
20. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8:1826.
21. Mooney S. Bioinformatics approaches and resources for single nucleotide polymorphism functional analysis. Brief Bioinform. 2005;6:44–56.
22. Nishida Y, Hachiya T, Hara M, Shimaoe C, Tanaka K, Sutoh Y, et al. The interaction between ABCA1 polymorphism and physical activity on the HDL-cholesterol levels in a Japanese population. J Lipid Res. 2020;61:86–94.
23. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The regression growth evaluation statin study group. N Engl J Med. 1998;338:86–93.
24. Barter PJ, Rye KA. Cholesteryl ester transfer protein, high density lipoprotein and arterial disease. Curr Opin Lipidol. 2001;12:73–82.
25. Kakko S, Tamminen M, Paivänsalo M, Kauma H, Rantalai AO, Lilja M, et al. Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. Eur J Clin Investig. 2001;31:593–602.
26. Park KW, Choi JH, Kim HK, Oh S, Chae IH, Kim HS, et al. The association of cholesteryl ester transfer protein polymorphism with high-density lipoprotein cholesterol and coronary artery disease in Koreans. Clin Genet. 2003;63:31–8.
27. Anagnostopoulou KK, Kolovou GD, Kostakou PM, Mihais C, Hatzigeorgiou G, Marvaki C, et al. Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia. Lipids Health Dis. 2009;8:24.
28. Papp AC, Pinsonneault JK, Wang D, Newman LC, Gong Y, Johnson JA, et al. Cholesterol ester transfer protein (CETP) polymorphisms affect miRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One. 2012;7:e31930.
29. Gamache I, Legault MA, Grenier JC, Sanchez R, Rheaume E, Asigan S, et al. A sex-specific evolutionary interaction between ADCY9 and CETP. Elife. 2021;10:e69198.
30. Kark JC, Sinnerich R, Leitersdorf E, Friedlander Y, Shpitzen S, Luc G. Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol. Atheroscler. 2000;151:509–18.
31. Herrera E, Amusquivar E, López-Soldado I, Ortega H. Maternal lipid metabolism and placental lipid transfer. Horm Res. 2006;65(Suppl 3):59–64.
32. Zhang C, Zhuang Y, Qiang H, Liu X, Xu R, Wu Y. Relationship between endogenous estrogen concentrations and serum cholesteryl ester transfer protein concentrations in Chinese women. Chin Clin Acta. 2001;314(1):77–83.
33. Bayrak A, Aldemir DA, Bayrak T, Corakci A, Dursun P. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women. Arch Gynecol Obstet. 2006;274:289–96.
34. Ambikairajah A, Walsh E, Cherbuin N. Lipid profile differences during menopause: a review with meta-analysis. Menopause. 2019;26:1327–33.
35. Nilsson SK, Heeren J, Olvecrorna G, Mørk M. Apolipoprotein A-V, a potent triglyceride reducer. Atherosclerosis. 2011;219:15–21.
36. Beckstead JA, Oda MN, Martin DD, Forte TM, Bielick JK, Berger T, et al. Structure-function studies of human apolipoprotein A-V: a regulator of plasma lipid homeostasis. Biochem. 2003;42:9416–23.
37. Lee KH, Kim OY, Lim H, Hwang J, Jang Y, Lee JH. Contribution of APOA5-1131C allele to the increased susceptibility of diabetes mellitus in association with higher triacylglyceride in Korean women. Metab. 2010;59:1583–90.
38. Chen H, Ding S, Zhou M, Wu X, Liu X, Wu Y, et al. Association of rs662799 in APOA5 with CAD in Chinese Han population. BMC Cardiovasc Disord. 2021;18:2.
39. Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. BMJ Glob Health. 2017;2:e000298.
40. Ye H, Zhou A, Hong Q, Tang L, Xu K, Xin Y, et al. Positive association between APOA5 rs662799 polymorphism and coronary heart disease: a case-control study and meta-analysis. PLoS One. 2015;10:e0135683.
41. Jiang CQ, Liu B, Cheung BM, Lam TH, Lin JM, Li Jin Y, et al. A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese. Eur J Hum Genet. 2010;18:1255–60.

42. Elbers CC, Guo Y, Tragante V, van Iperen EP, Lanktree MB, Castillo BA, et al. Gene-centric meta-analysis of lipid traits in African, east Asian and Hispanic populations. PLoS One. 2012;7:e50198.

43. Gombojav B, Lee SJ, Kho M, Song YM, Lee K, Sung J. Multiple susceptibility loci at chromosome 11q23.3 are associated with plasma triglyceride in east Asians. J Lipid Res. 2016;57:318–24.

44. Park JM, Park DH, Song Y, Kim JO, Choi JE, Kwon YJ, et al. Understanding the genetic architecture of the metabolically unhealthy normal weight and metabolically healthy obese phenotypes in a Korean population. Sci Rep. 2021;11:2279.

45. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 2009;297:E271–E88.

46. Pirim D, Wang X, Redwan ZH, Niemisri V, Hokanson JE, Hamman RF, et al. Lipoprotein lipase gene sequencing and plasma lipid profile. J Lipid Res. 2014;55:85–93.

47. Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26:56–63.

48. Zhen J, Huang X, Van Halm-Lutterodt N, Dong S, Ma W, Xiao R, et al. ApoE rs429358 and rs7412 polymorphism and gender differences of serum lipid profile and cognition in aging Chinese population. Front Aging Neurosci. 2017;9:248.

49. Seo JY, Youn BJ, Cheong HS, Shin HD. Association of APOE genotype with lipid profiles and type 2 diabetes mellitus in a Korean population. Genes & Genomics. 2021;43:725–35.

50. Son KY, Son HY, Chae J, Hwang J, Jung S, Yun JM, et al. Genetic association of APOA5 and APOE with metabolic syndrome and their interaction with health-related behavior in Korean men. Lipids Health Dis. 2015;14:105.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.